Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Katherine Eason

Benefit From Anti-EGFRs in RAS and BRAF Wild-Type Metastatic Transverse Colon Cancer: A Clinical and Molecular Proof of Concept Study

ESMO Open
Cancer ResearchOncology
2019English

polyClustR: Defining Communities of Reconciled Cancer Subtypes With Biological and Prognostic Significance

BMC Bioinformatics
BiochemistryApplied MathematicsComputer Science ApplicationsStructural BiologyMolecular Biology
2018English

Related publications

RAS and BRAF in Metastatic Colorectal Cancer Management

Journal of Gastrointestinal Oncology
OncologyGastroenterology
2016English

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-Line Cetuximab and Irinotecan

JAMA Oncology
Cancer ResearchOncology
2019English

Sequential HER2 Blockade as Effective Therapy in Chemorefractory, HER2 Gene-Amplified, RAS Wild-Type, Metastatic Colorectal Cancer: Learning From a Clinical Case

ESMO Open
Cancer ResearchOncology
2018English

Mutant and Wild-Type Ras: Co-Conspirators in Cancer

Cancer Discovery
Oncology
2013English

Relationship Between Tumour Response and Tumour-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials

Clinical Colorectal Cancer
OncologyGastroenterology
2019English

Impact of Tumour RAS/BRAF Status in a First-Line Study of Panitumumab + FOLFIRI in Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2016English

PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2012English

FOLFIRI Plus Panitumumab in the Treatment of Wild-Type KRAS and Wild-Type NRAS Metastatic Colorectal Cancer

World Journal of Surgical Oncology
SurgeryOncology
2018English

The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-Ras Mutation Status: Analysis of a Phase III Study of Bevacizumab With Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy